Latest news articles

Added 1 year ago Drug news

FDA approves Bijuva to treat moderate to severe vasomotor symptoms due to menopause. Therapeutics MD

Therapeutics MD, Inc. announced that the FDA has approved Bijuva (estradiol and progesterone) capsules, 1 mg/100 mg, the first and...

Added 1 year ago Drug news

TX 001HR for the treatment of moderate-to-severe vasomotor symptoms due to menopause has PDUFA date of 28 October 2018.- Therapeutics MD

Therapeutics MD, Inc. announced that the Company has entered into discussions with the FDA regarding the proposed label for TX...

Added 2 years ago Drug news

Oestradiol refiled with FDA for vaginal pain due to menopause

TherapeuticsMD has resubmitted the New Drug Application (NDA) for TX004HR (oestradiol).

Search all news articles for Menopausal disorders

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Load more


Menopause: diagnosis and management

This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.

Added 4 years ago

Search all guidelines for Menopausal disorders

Journal articles

Effects of ospemifene on vaginal epithelium of post-menopausal women.

Ospemifene is a selective estrogen receptor modulator used for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. No direct evidence of its effects on histological features of the human vagina has been reported.

Added 2 years ago

Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.

In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio®) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA).

Added 2 years ago

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy.

The physiological decrease in vaginal estrogens is accountable for the emergence of vulvar and vaginal atrophy (VVA) and its related symptoms such as vaginal dryness, dyspareunia, vaginal and/or vulvar irritation or itching, and dysuria.

Added 2 years ago

Search all journal articles for Menopausal disorders


Test your knowledge of recent NICE guidance

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
Registration required
Subscription fee
Search all CME for Menopausal disorders